

Amendments to the Claims:

Please enter new Claims 71 and 72.

1-63. (Cancelled)

64. (Previously presented) A method of inducing apoptosis in cancer cells of a recipient mammal, comprising:

introducing into said mammal a pharmaceutically acceptable carrier comprising a recombinant viral vector comprising a nucleic acid sequence encoding Fas ligand operatively linked to a transcription control sequence,

wherein said recombinant viral vector expresses Fas ligand,

wherein said cancer cells are metastatic cancer cells, and

wherein expression of Fas ligand induces apoptosis in said metastatic cancer cells.

65. (Cancelled)

66. (Previously presented) The method of Claim 64, wherein said cancer is selected from the group consisting of lung cancer, brain cancer, prostate cancer, and lymphoma.

67-68. (Cancelled)

69. (Previously Presented) The method of Claim 64, wherein said recombinant viral vector is from an adenovirus.

70. (Cancelled)

71. (New) A method of treating metastatic cancer in a mammal, comprising:

introducing into said mammal a pharmaceutically acceptable carrier comprising a recombinant viral vector comprising a nucleic acid sequence encoding Fas ligand operatively linked to a transcription control sequence,

wherein said recombinant viral vector expresses Fas ligand, and

wherein expression of Fas ligand induces apoptosis in cells of said metastatic cancer.

72. (New) The method of Claim 71, wherein said pharmaceutically acceptable carrier comprising a recombinant viral vector is introduced at a site adjacent to said metastatic cancer cells.